Exact Sciences announced today that approximately 40,000 Cologuard tests were completed in the first quarter of 2016.

“Our first quarter performance reflects sequential growth and another significant year-over-year increase, the result of continued progress optimizing the drivers of our commercial strategy,” Exact Sciences Chairman and CEO Kevin Conroy said in a statement.”Throughout the quarter, our efforts were focused on delivering compelling marketing programs, improving salesforce effectiveness and securing broad commercial reimbursement for Cologuard. We are pleased with the progress being made in each area.”

According to a release, the number of tests was a 263 percent increase over the 11,000 tests conducted in the first quarter of 2015.